The Brain and Heart Symposium

Speaker Information

All times refer to Nevada Time (Pacific Standard Time).

SPeaker	Topic & Time
Saturday, November 16- Registration, Breakfast and Vendor Exhibit	7:30 AM
David Wang, DO Vijendra Swarup, MD, FACC, FHRS Robert Lemery, MD Chowdhury Ahsan, MD	Welcome and Introductions to Brain-Heart (7:55 AM)
Moderators: Vijendra Swarup, MD; Dhanujaya R. Lakkireddy, MD	Session I: Atrial Fibrillation and Stroke Prevention: Strategies and Innovations
Robert Lemery, MD	The Autonomic Nervous System, Neurocardiology and Atrial Fibrillation (8:00 AM)
Sudarone Thihalolipavan, MD	AF Surveillance in the Digital Age (8:10 AM)
Arash Aryana, MD	Pulsed Field Ablation in the EP Lab: Safeguarding the Esophagus While Sparing Cardiac Ganglia? (8:20 AM)
Supreet Kaur, MD	Embolic Strokes of Unknown Source (ESUS): Controversies in Diagnosis, Risk, and Treatment (8:30 AM)
Sabil Kar, MD	Atrial Fibrillation and Stroke Prevention (Debate): The Interventional Approach: Left Atrial Appendage Occlusion: PRO (8:40 AM)
Dhanujaya R. Lakkireddy, MD	Atrial Fibrillation and Stroke Prevention (Debate): The Pharmacologic Approach: Anticoagulants and Beyond: PRO (8:50 AM)
Vijendra Swarup, MD	Atrial Fibrillation and Stroke Prevention (Debate): Consensus & Clinical Key Points (9:00 AM)
Robert Lemery, MD Sudarone Thihalolipavan, MD Arash Aryana, MD Supreet Kaur, MD Sabil Kar, MD Dhanujaya R. Lakkireddy, MD Vijendra Swarup, MD	Panel Discussion and Q&A (9:10 AM)
Moderator: David Wang, DO; Vijendra Swarup, MD; Robert Lemery, MD	Session II: Feature Presentation
M. Edip Gurol, MD, MSc	Tailored Stroke Prevention in Atrial Fibrillation: Neuroimaging, Precision Cardiology and the intersection of Neurology and Cardiology (9:30 AM)
M. Edip Gurol, MD, MSc	Questions and Comments (9:50 AM)
Break	10:00 AM
Moderators: M. Edip Gurol, MD, MSc; Arash Aryana, MD	Session III: Stroke Prevention, Therapeutic Interventions, and Managing Brain Bleeds
David Wang, DO	Pharmacological Strategies in Stroke Management: Integration of Antiplatelet, Anticoagulant, and Neuroprotective Therapies to Limit Stroke Damage While Managing Bleeding Risks (10:30 AM)
Ahsan Chowdhary, MD	Harnessing Incretin-Based Therapies: Transformative Impact of GLP-1 Receptor Agonists in Cardiovascular and Stroke Prevention (10:40 AM)
Saibal Kar, MD	Interatrial Septal Defect Closure: Updated Guidelines for Managing Patients with Cryptogenic Stroke, Migraine, Scuba Diving, and Other Clinical Scenarios (10:50 AM)
Deanne Sasaki-Adams, MD	Surgical Interventions in Intracerebral Hemorrhage: Indications and Outcomes – ENRICH Trial (11:00 AM)
Paige Banyas, MD	Thrombectomy for Stroke: Expanding the Criteria for Intervention in Large Vessel Occlusion with Low ASPECTS Score (11:10 AM)
David Wang, DO	Aggressive Lipid Lowering After Stroke: Pushing Boundaries for Enhanced Recovery and Secondary Prevention (11:20 AM)
David Wang, DO Ahsan Chowdhary, MD Saibal Kar, MD Paige Banyas, MD Srijoy Mahapatra, MD	Panel Discussion and Q&A (11:40 AM)
Lunch	12:00 PM
Moderator: David Kennigsberg, MD; Robert Lemery, MD	Session IV: Syncope, Cardiac Arrest, Heart Failure, and Amyloid Disease: Intersecting Pathologies of the Brain and Heart
Justin Hoskin, MD	The Brain Is in Charge: Basic Understanding of the Sympathetic and Parasympathetic Nervous Systems (1:00 PM)
Robert Lemery, MD	The Heart Is in Charge: The Concept of the Little Brain on the Heart – The Intrinsic Cardiac Nervous System (1:10 PM)
Win Shen, MD	Neuro-Cardiogenic Syncope and Dysautonomia: Advanced Insights into Autonomic Dysfunction and Comprehensive Management Strategies (1:20 PM)
Sudarone Thihalolipavan, MD	Cardiogenic Syncope and Sudden Cardiac Death: New Leadless Pacing and Extravascular ICD technologies (1:30 PM)
David Harris, MD	Sudden Unexpected Death: Unraveling the Brain’s Role in Fatal Outcomes (1:40 PM)
Yonas E. Geda, MD, MSc	Amyloid Disease in the Brain and Heart: Strategies for Removing Beta Amyloid in Neurodegenerative Disorders (1:50 PM)
Sanjay Malhotra, MD	Amyloid Disease in the Brain and Heart: Stabilizing Transthyretin Protein in Cardiac Amyloidosis (2:00 PM)
Justin Hoskin, MD Win Shen, MD Sudarone Thihalolipavan, MD David Harris, MD Yonas E. Geda, MD, MSc Sanjay Malhotra, MD	Panel Discussion and Q&A (2:10 PM)
Break	2:30 PM
Moderators: Arash Aryana, MD; Vijendra Swarup, MD	Session V: Bridging Neurology and Cardiology: Advances in Neuromodulation Therapies
Lin Zhang, MD	Deep Brain Stimulation for Essential Tremor and Parkinson’s Disease (2:40 PM)
Christina Kwasnica, MD	Deep Brain Stimulation: A New Frontier in Stroke Rehabilitation (2:50 PM)
Win Shen, MD	Neuromodulation for Syncope: The Emerging Role of Catheter Ablation of Cardiac Nerves and Ganglia (3:00 PM)
Moussa Mansour, MD	Neuromodulation for Atrial Fibrillation: Ablation of Cardiac Nerves and Ganglia, and Tragus Nerve Stimulation (3:10 PM)
Suneet Mittal, MD	Neuromodulation in Hypertension: Renal Nerve Denervation (3:20 PM)
David Kenigsberg, MD	Neuromodulation in Congestive Heart Failure: Carotid Baroreceptor Stimulation and Cardiac Contractility Modulation (3:50 PM)
Dhanunjaya Lakkireddy, MD	Neuromodulation for Ventricular Tachycardia and Fibrillation: Anesthesia, Stellate Ganglion Block, and Thoracoscopic Sympathetic Denervation (4:00 PM)
Lin Zhang, MD Christina Kwasnica, MD Dhanunjaya Lakkireddy, MD Win Shen, MD Suneet Mittal, MD David Kenigsberg, MD Moussa Mansour, MD	Panel Discussion and Q&A (4:10 PM)
Moderators: Devi Nair, MD, Andrea Natale, MD	Session VI: Innovations in Cardiovascular and Neurological Care: AI, Ambulatory Surgery Centers, Arrhythmia Interventions
Srijoy Mahapatra, MD	The Promise and Peril of Artificial Intelligence in Invasive Medicine (4:30 PM)
David Wang, DO	Low-Field MRI for Diagnosis of Stroke Care: Revolutionizing Detection, Diagnosis, and Intervention (4:40 PM)
Vijendra Swarup, MD	Ambulatory Surgical Centers and the Future of Arrhythmia Intervention for Stroke Prevention (4:50 PM)
Arash Aryana, MD	The Arrhythmia Intervention Society (AIS): A New Society for Advocacy of Patient Care and Physician Representation (5:00 PM)
All Panelists	Panel Discussion and Q&A (5:10 PM)
Adjourn	5:25 PM

Commercial Promotion

• No commercial support has been received.

Exhibitors and Sponsors

• Those interested in exhibiting or sponsorship should contact CME@BarrowNeuro.org for more information.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any ineligible company held in the last 24 months. Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.